Monopar Therapeutics’ (MNPR) Buy Rating Reiterated at HC Wainwright

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $105.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 19.75% from the company’s current price.

A number of other equities analysts have also issued reports on the stock. Chardan Capital reiterated a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $107.91.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $87.68 on Monday. The stock has a 50-day simple moving average of $62.26 and a 200 day simple moving average of $62.03. Monopar Therapeutics has a 12-month low of $29.18 and a 12-month high of $105.00. The stock has a market capitalization of $587.46 million, a price-to-earnings ratio of -46.15 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.41. As a group, sell-side analysts anticipate that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its holdings in Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares during the period. ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares during the period. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics during the first quarter worth about $250,000. Siren L.L.C. boosted its holdings in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares during the last quarter. Finally, Sei Investments Co. grew its position in shares of Monopar Therapeutics by 9.5% during the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares during the period. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.